Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-097558 in Subjects With Moderate Hepatic Impairment and in Healthy Subjects
NCT06568861Phase 1Completed
- Sponsor
- Aligos Therapeutics
- Start
- Jan 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ALG-097558 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Aligos Therapeutics. Primary endpoints: Area Under the Concentration Time Curve at Day 6, Time to Maximum Plasma Concentration at Day 6 and 4 more. Started Jan 2025; status: completed.
02
Drugs
ALG-097558
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06568861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568861.